Combined modality treatment for central nervous system malignancies.
This review summarizes the current status and future prospects for combined modality treatment of primary and metastatic central nervous system malignancies. The laboratory and clinical basis for multimodality therapy, including surgery, ionizing radiation, and drug therapy, are outlined and critically reviewed. The central nervous system diseases discussed include: glioma (low and high grade), brain metastases, and primary central nervous system lymphoma. Collectively, these data suggest a shift favoring combined modality approaches in several of these diseases; however, the incremental gains are indeed modest. The individual practitioner must weigh these with the additional toxicities before making a therapeutic decision for a particular patient. The future direction of combined modality therapy in these diseases will likely revolve around the increased use of molecular diagnostics resulting in the application of targeted therapy. Clearly, such promising innovations must be delineated in the context of continued preclinical studies and controlled clinical trials.
Robins
H Ian
HI
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA.
Peterson
Christopher G
CG
Mehta
Minesh P
MP
D000328:Adult; D001254:Astrocytoma / Q000628:therapy; D001932:Brain Neoplasms / Q000556:secondary; D016543:Central Nervous System Neoplasms / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005910:Glioma / Q000628:therapy; D006801:Humans; D008223:Lymphoma / Q000628:therapy